Heterologous mRNA-based COVID-19 booster strategies: Comment
- PMID: 36798966
- PMCID: PMC10026856
- DOI: 10.1080/21645515.2023.2174758
Heterologous mRNA-based COVID-19 booster strategies: Comment
Conflict of interest statement
No potential conflict of interest was reported by the author(s).
Comment on
-
Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscape.Hum Vaccin Immunother. 2023 Dec 31;19(1):2153532. doi: 10.1080/21645515.2022.2153532. Epub 2023 Jan 11. Hum Vaccin Immunother. 2023. PMID: 36629006 Free PMC article.
References
-
- Čiučiulkaitė I, Möhlendick B, Thümmler L, Fisenkci N, Elsner C, Dittmer U, Siffert W, Lindemann M.. GNB3 c.825c>T polymorphism influences T-cell but not antibody response following vaccination with the mRNA-1273 vaccine. Front Genet. 2022. Aug 29;13:932043. doi:10.3389/fgene.2022.932043. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical